Cipla Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/t4c7vzmbru1dx3nx5j2ihp5t.pdf

Key Takeaways


US Formulations: Record Quarter & Pipeline Catalyst

Vohra: "Our target action date is hopefully in the first week of April. So I think we are quite looking forward to being able to bring the product to the market and it's the first week of April."

One India: Consistent Market-Beating Growth


International Markets: SAGA Drag, DTM Resilience

Vohra: "So my guess is this is the worst is probably in our numbers over the last two quarters. And I think we'll begin to see a resumption to normal."

Margins: Peak Quarter, Reinvestment Mandate

Vohra: "Our intention is to grow margins year-on-year. I think the pace of growth, as we've said earlier, that since we've reached the level of the 21% to 22% now, I think the objective is also to reinvest back in the business and to try and see if we can increase the margin profile further from here because we'd like to invest back to grow business faster."

Pipeline & Strategic Bets


Capital Allocation: Surplus Cash, India-First M&A


Guidance & Commitments

CommitmentSpecificsTimeline
Advair approvalTarget action date in first week of April; management feels closer to approval after responding to minor query in second review cycleFirst week of April 2023
US quarterly baseGuided to a base of about $185–190 mnQ4 FY23
Full-year EBITDA marginIn line with guidance of 21% to 22%FY23
R&D spendRemain at ~6–7% of sales; absolute spend to inch up graduallyOngoing
South Africa recoveryWorst is in the numbers; resumption to normal expectedQ1 FY24
Complex US launchesAdvair, Abraxane, one peptide product by September are the larger onesNext 15 months
US revenue ambitionReach $900 mn from current ~$700 mn 12-month run rateOver a period of time
Biosimilars (non-regulated markets)Potential launchesNext 3–4 years
Biosimilars (regulated markets)Potential launches5–6 years out

Key Metrics

MetricQ3 FY23
Revenue₹5,810 cr, +6% YoY reported; +11% YoY COVID-adjusted
EBITDA margin24%+, +13% YoY reported EBITDA growth; +24% YoY COVID-adjusted
Gross margin65.5%, +450 bps YoY, driven by new launches and mix change
R&D spend₹363 cr (6.2% of revenue), +₹100+ cr YoY
Profit after tax (reported)₹801 cr (13.8% of sales), includes one-time deferred tax asset reversal
Profit after tax (adjusted)₹876 cr (15.1% of sales), +20% YoY adjusted growth
One India core portfolio growth+11% YoY, COVID-adjusted; seventh consecutive quarter of market-beating growth
US core formulation sales$195 mn, highest ever quarterly revenue, +30% YoY
Lanreotide market share14.1%, as of Nov '22 end; on track for 15% guidance
Albuterol market share18%, as per IQVIA week ending Dec 31, 2022
Arformoterol market share39%, as per IQVIA week ending Dec 31, 2022
India consumer franchise growth+14% YoY, INR terms, adjusted for Q2 FY23 acquisition
Global consumer franchise share~9% of overall Cipla revenue
Chronic share of One India Rx60% of mix, expanded 240 bps YoY
Brands >₹100 cr (trailing 12M)21 brands, vs 19 in the corresponding previous period
Return on capital employed19.7%, trailing 12 months; tracking closer to 20%
South Africa private market share7.7%, third market position